DÄ internationalArchive24/2020Clinical practice guideline: Schizophrenia

Clinical Practice Guideline

Clinical practice guideline: Schizophrenia

Dtsch Arztebl Int 2020; 117: 412-9. DOI: 10.3238/arztebl.2020.0412

Hasan, A; Falkai, P; Lehmann, I; Gaebel, W

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Klinik für Psychiatrie, Psychotherapie und Psychosomatik der Universität Augsburg, Medizinische Fakultät, Bezirkskrankenhaus Augsburg, Augsburg: Prof. Dr. med. Alkomiet Hasan
Klinik für Psychiatrie und Psychotherapie, LMU Klinikum München, München:
Prof. Dr. med. Alkomiet Hasan, Prof. Dr. med. Peter Falkai
LVR-Institut für Versorgungsforschung, Köln: Dr. Isabell Lehmann
Klinik und Poliklinik für Psychiatrie und Psychotherapie, LVR-Klinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Medizinische Fakultät, Düsseldorf: Prof. Dr. med. Wolfgang Gaebel
1.Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN): S3-Leitlinie Schizophrenie. AWMF-Register Nr. 038–009. www.awmf.org/leitlinien/detail/ll/038-009.html (last accessed on 15 March 2019).
2.Simon GE, Stewart C, Yarborough BJ, et al.: Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiatry 2018; 75: 254–60 CrossRef MEDLINE PubMed Central
3.Plana-Ripoll O, Pedersen CB, Agerbo E, et al.: A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. Lancet 2019; 394: 1827–35 CrossRef
4.DeHert M, Correll CU, Bobes J, et al.: Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10: 52–77 CrossRef MEDLINE PubMed Central
5.De Hert M, Cohen D, Bobes J, et al.: Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011; 10: 138–51 CrossRef MEDLINE PubMed Central
6.Caldwell CB, Gottesman II: Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophrenia Bull 1990; 16: 571–89 CrossRef MEDLINE
7.Siris SG: Suicide and schizophrenia. J Psychopharmaco 2001; 15: 127–35 CrossRef MEDLINE
8.Meltzer HY: Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. J Clin Psychiatry 2005; 66: 530–3 CrossRef MEDLINE
9.Pompili M, Amador XF, Girardi P, et al.: Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry 2007; 6: 10 CrossRef MEDLINE PubMed Central
10.Pompili M, Lester D, Grispini A, et al.: Completed suicide in schizophrenia: evidence from a case-control study. Psychiatry Res 2009; 167: 251–7 CrossRef MEDLINE
11.Hasan A, Falkai P, Wobrock T, et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 2015; 16: 142–70 CrossRef MEDLINE
12.Nordentoft M, Jeppesen P, Abel M, et al.: OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis. One-year follow-up of a randomised controlled trial. Br J Psychiatry Suppl 2002; 43: s98–106 CrossRef MEDLINE
13.Crump C, Winkleby MA, Sundquist K, Sundquist J: Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 2013; 170: 324–33 CrossRef MEDLINE
14.Buckley PF, Miller BJ, Lehrer DS, Castle DJ: Psychiatric comorbidities and schizophrenia. Schizophrenia Bull 2009; 35: 383–402 CrossRef MEDLINE PubMed Central
15.Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN): S3-Leitlinie: Screening, Diagnostik und Behandlung des schädlichen und abhängigen Tabakkonsums 2015. www.awmf.org/leitlinien/detail/ll/076-006.html (last accessed on 19 January 2020).
16.Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB: Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: systematic review and meta-analysis. Drug Alcohol Depend 2018; 191: 234–58 CrossRef MEDLINE
17.Fazel S, Khosla V, Doll H, Geddes J: The prevalence of mental disorders among the homeless in western countries: systematic review and meta-regression analysis. PLoS Med 2008; 5: e225 CrossRef MEDLINE PubMed Central
18.Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN): S3-Leitlinie Schizophrenie: Leitlinienreport. www.awmf.org/uploads/tx_szleitlinien/038-009m_S3_Schizophrenie_2019-03.pdf (last accessed on 19 January 2020).
19.Richardson WS, Wilson MC, Nishikawa J, Hayward RS: The well-built clinical question: a key to evidence-based decisions. ACP journal club 1995; 123: A12–3.
20.National Institute for Health and Care Excellence (NICE): NICE clinical guideline 178 – Psychosis and schizophrenia in adults: treatment and management – Issued: February 2014, last modified: March 2014. guidance.nice.org.uk/cg178 (last accessed on 27 December 2019).
21.National Institute for Health and Care Excellence (NICE): Psychosis and schizophrenia in children and young people: recognition and management. www.ncbi.nlm.nih.gov/books/NBK299073/ (last accessed on 19 January 2020).
22.National Institute for Health and Care Excellence (NICE): Violence and aggression: short-term management in mental health, health and community settings. 2015.www.nice.org.uk/guidance/ng10 (last accessed on 19 January 2020).
23.Scottish Intercollegiate Guidelines Network (SIGN): SIGN 131. Management of schizophrenia. A national clinical guideline 2013. www.sign.ac.uk/sign-131-management-of-schizophrenia (last accessed on 14 July 2019).
24.Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN): S3 Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankung – 2013er Version und Teile der revidierten 2018er Version lagen der Leitliniengruppe vor. 2013/18. www.awmf.org/leitlinien/detail/ll/076-001.html (last accessed on 19 January 2020).
25.Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN): Screening, Diagnose und Behandlung alkoholbezogener Störungen: Springer; 2016. www.awmf.org/leitlinien/detail/ll/038-020.html (last accessed on 19 January 2020).
26.Gaebel W: Status of psychotic disorders in ICD-11. Schizophr Bull 2012; 38: 895–8 CrossRef MEDLINE PubMed Central
27.Leucht S, Tardy M, Komossa K, et al.: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063–71 CrossRef
28.Leucht S, Leucht C, Huhn M, et al.: Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 2017; 174: 927–42 CrossRef MEDLINE
29.Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC: Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull 2011; 37: 788–99 CrossRef MEDLINE PubMed Central
30.Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU: Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012; 138: 18–28 CrossRef MEDLINE PubMed Central
31.Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM: Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry 2019: appiajp201919010034 CrossRef MEDLINE
32.Leucht S, Cipriani A, Spineli L, et al.: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951–62 CrossRef
33.Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al.: Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939–51 CrossRef
34.Schneider-Thoma J, Efthimiou O, Huhn M, et al.: Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry 2018; 5: 653–63 CrossRef
35.Bighelli I, Salanti G, Huhn M, et al.: Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. World Psychiatry 2018; 17: 316–29 CrossRef MEDLINE PubMed Central
36.McCutcheon RA, Pillinger T, Mizuno Y, et al.: The efficacy and heterogeneity of antipsychotic response in schizophrenia: a meta-analysis. Mol Psychiatry 2019. [Epub ahead of print CrossRef
37.Pillinger T, McCutcheon RA, Vano L, et al.: Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020; 7: 64–77 CrossRef
38.Zhu Y, Li C, Huhn M, et al.: How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2017; 27: 835–44 CrossRef MEDLINE
39.Deutsche Gesellschaft für Psychiatrie und Psychotherapie und Nervenheilkunde (DGPPN): S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1 – Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff-Verlag 2006.
e1.De Hert M, Sermon J, Geerts P, Vansteelandt K, Peuskens J, Detraux J: The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with Schizophrenia: A systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics. CNS Drugs 2015; 29: 637–58 CrossRef MEDLINE
e2.Samara MT, Leucht C, Leeflang MM, et al.: Early improvement as a predictor of later esponse to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 2015; 172: 617–29 CrossRef MEDLINE
e3.Samara MT, Dold M, Gianatsi M, et al.: Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry 2016; 73: 199–210 CrossRef MEDLINE
e4.Siskind D, McCartney L, Goldschlager R, Kisely S: Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016; 209: 385–92 CrossRef MEDLINE
e5.Buchanan RW, Kreyenbuhl J, Kelly DL, et al.: The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bull 2010; 36: 71–93 CrossRef MEDLINE PubMed Central
e6.Hasan A, Falkai P, Wobrock T, et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13: 318–78 CrossRef MEDLINE
e7.Dold M, Fugger G, Aigner M, Lanzenberger R, Kasper S: Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Res 2015; 166: 187–93 CrossRef MEDLINE
e8.Galling B, Roldan A, Hagi K, et al.: Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 2017; 16: 77–89 CrossRef MEDLINE PubMed Central
e9.Wang Y, Xia J, Helfer B, Li C, Leucht S: Valproate for schizophrenia. Cochrane Database Syst Rev 2016; 11: CD004028 CrossRef PubMed Central
e10.Leucht S, Helfer B, Dold M, Kissling W, McGrath JJ: Lithium for schizophrenia. Cochrane Database Syst Rev 2015: CD003834 CrossRef PubMed Central
e11.Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S: Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017; 74: 675–84 CrossRef MEDLINE PubMed Central
e12.Helfer B, Samara MT, Huhn M, et al.: Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 2016; 173: 876–86 CrossRef MEDLINE
e13.Xia J, Merinder LB, Belgamwar MR: Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2011: CD002831 CrossRef PubMed Central
e14.Bird V, Premkumar P, Kendall T, Whittington C, Mitchell J, Kuipers E: Early intervention services, cognitive-behavioural therapy and family intervention in early psychosis: systematic review. Br J Psychiatry 2010; 197: 350–6 CrossRef MEDLINE PubMed Central
e15.Wykes T, Steel C, Everitt B, Tarrier N: Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008; 34: 523–37 CrossRef MEDLINE PubMed Central
e16.Eichner C, Berna F: Acceptance and efficacy of metacognitive training (MCT) on positive symptoms and delusions in patients with schizophrenia: a meta-analysis taking into account important moderators. Schizophr Bull 2016; 42: 952–62 CrossRef MEDLINE PubMed Central
e17.Pinquart M, Oslejsek B, Teubert D: Efficacy of systemic therapy on adults with mental disorders: a meta-analysis. Psychother Res 2016; 26: 241–57 CrossRef MEDLINE
e18.Turner DT, McGlanaghy E, Cuijpers P, van der Gaag M, Karyotaki E, MacBeth A: A meta-analysis of social skills training and related interventions for psychosis. Schizophr Bull 2017 CrossRef MEDLINE PubMed Central
e19.Rosenbaum B, Harder S, Knudsen P, et al.: Supportive psychodynamic psychotherapy versus treatment as usual for first-episode psychosis: two-year outcome. Psychiatry 2012; 75: 331–41 CrossRef MEDLINE
e20.Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P: A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011; 168: 472–85 CrossRef MEDLINE
e21.Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN): S3 Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen. www.awmf.org/leitlinien/detail/ll/038-020.html (last accessed on 19 January 2020).
e22.Correll CU, Solmi M, Veronese N, et al.: Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3 211 768 patients and 113 383 368 controls. World Psychiatry 2017; 16: 163–80 CrossRef MEDLINE PubMed Central
e23.Leucht S, Burkard T, Henderson J, Maj M, Sartorius N: Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007; 116: 317–33 CrossRef MEDLINE
e24.Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS: Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72: 1172–81 CrossRef MEDLINE
e25.Galling B, Roldan A, Nielsen RE, et al.: Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry 2016; 73: 247–59 CrossRef MEDLINE
e26.Bitter I, Czobor P, Borsi A, et al.: Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study. Eur Psychiatry 2017; 45: 97–103 CrossRef MEDLINE
e27.Vancampfort D, Correll CU, Galling B, et al.: Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 2016; 15: 166–74 CrossRef MEDLINE PubMed Central
e28.Vancampfort D, Stubbs B, Mitchell AJ, et al.: Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015; 14: 339–47 CrossRef MEDLINE PubMed Central
e29.Li H, Li J, Yu X, et al.: The incidence rate of cancer in patients with schizophrenia: a meta-analysis of cohort studies. Schizophr Res 2018; 195: 519–28 CrossRef MEDLINE
e30.Vancampfort D, Wampers M, Mitchell AJ, et al.: A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013; 12: 240–50 CrossRef MEDLINE PubMed Central
e31.Stubbs B, Vancampfort D, De Hert M, Mitchell AJ: The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015; 132: 144–57 CrossRef PubMed Central
e32.Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M: Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull 2013; 39: 295–305 CrossRef MEDLINE PubMed Central
e33.Zareifopoulos N, Bellou A, Spiropoulou A, Spiropoulos K: Prevalence of comorbid chronic obstructive pulmonary disease in individuals suffering from schizophrenia and bipolar disorder: a systematic review. COPD 2018; 15: 612–20 CrossRef MEDLINE
e34.Kuo CJ, Yang SY, Liao YT, et al.: Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull 2013; 39: 648–57 CrossRef MEDLINE PubMed Central
e35.Hughes E, Bassi S, Gilbody S, Bland M, Martin F: Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry 2016; 3: 40–8 CrossRef
e36. Stubbs B, Vancampfort D, Veronese N, et al.: The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: a systematic review and meta-analysis. J Affect Disord 2016; 197: 259–67 CrossRef MEDLINE
e37.Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR: The prevalence of psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatry 2014; 14: 75 CrossRef MEDLINE PubMed Central
e38.Yang M, Chen P, He MX, et al.: Poor oral health in patients with schizophrenia: a systematic review and meta-analysis. Schizophr Res 2018; 201: 3–9 CrossRef MEDLINE
e39.Liao CH, Chang CS, Chang SN, et al.: The association of peptic ulcer and schizophrenia: a population-based study. J Psychosom Res 2014; 77: 541–6 CrossRef MEDLINE
e40.De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ: Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009; 24: 412–24 CrossRef MEDLINE
e41.Mukundan A, Faulkner G, Cohn T, Remington G: Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 2010; CD006629 CrossRefMEDLINE
e42.Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD: Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008; 193: 101–7 CrossRef MEDLINE
e43.Teasdale SB, Ward PB, Rosenbaum S, Samaras K, Stubbs B: Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. Br J Psychiatry 2017; 210: 110–8 CrossRef MEDLINE
e44.de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R: Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry 2016; 16: 341 CrossRef MEDLINE PubMed Central
e45.Mizuno Y, Suzuki T, Nakagawa A, et al.: Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014; 40: 1385–403 CrossRef MEDLINE PubMed Central
e46.Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S: Metformin for clozapine associated obesity: a systematic review and meta-analysis. PloS One 2016; 11: e0156208 CrossRef MEDLINE PubMed Central
e47.Mahmood S, Booker I, Huang J, Coleman CI: Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 2013; 33: 90–4 CrossRef MEDLINE
e48.Zheng W, Xiang YT, Xiang YQ, et al.: Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatr Scand 2016; 134: 385–98 CrossRef MEDLINE
e49.Müller MJ, Benkert O: Antipsychotika. In: Benkert O, Hippius H, (eds.): Kompendium der Psychiatrischen Pharmakotherapie. Berlin, Heidelberg: Springer Verlag 2017; 269–488 CrossRef PubMed Central
e50.Correll CU: Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47: 9–20 CrossRef PubMed Central
e51. Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU: Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry 2013; 26: 219–30 CrossRef MEDLINE